A postchemotherapy hyperammonemic encephalopathy emulating OTCD has been described as a distinct syndrome of hyperammonemia in two young women with hepatocellular carcinoma, who resulted mutation-negative to OTC [[42],[43]]. This evidence concerns the gene OTC and ornithine carbamoyltransferase deficiency.